Principal investigator Hülya Bayır, MD and co-investigators (Robert Clark, MD; Qin Yang, MD; Michael Epperly, PhD; Wipf, PhD; Yulia Tyurina, PhD; Haider Dar, PhD; Galina Shurin, PhD; Shrivastava, PhD; and Dr. Ganesha Bantukallu, PhD) received U01 funding from the National Institute of Allergy and Infectious Diseases to combat multi-system effects of ionizing radiation.

The project titled “Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis” emphasizes the necessity for protection against ionizing radiation that comes from terrorism, nuclear accidents, occupational exposures, and radiotherapy.

There is emerging need for new medical products that can mitigate and/or treat the short- and long-term consequences of radiation exposure. “The overall goal of this project is to investigative the radiomitigative potential of small molecule compounds that inhibit regulated cell death pathways triggered by irradiation. We will investigate how irradiation is triggering regulated cell death, and test existing and new drugs in their effectiveness to mitigate radiation disease when given 24h after exposure” said Hülya Bayır, MD, who is the director of the Children’s Neuroscience Institute, Academic Chief and Director of Research and professor of Critical Care Medicine, Environmental and Occupational Health, and Pediatrics.